• Revelation Biosciences posted a net loss of USD 3.01 million for the three months ended March 31, 2026, widening from USD 2.05 million a year earlier.
• Operating loss widened to USD 3.09 million as total operating expenses climbed to USD 3.09 million.
• Research and development expense rose to USD 1.38 million due to higher GEM-AKI program and manufacturing spend, new-facility costs, and higher personnel expense, partly offset by lower GEM-CKD program expense.
• General and administrative costs increased to USD 1.72 million on higher personnel expense and professional fees tied to the new facility lease.
• Cash and cash equivalents totaled USD 14.1 million at March 31, 2026; management said the balance is not expected to fund operations for one year after issuance of the financial statements, raising substantial doubt about going-concern ability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-211871), on May 07, 2026, and is solely responsible for the information contained therein.